|
Dyne Therapeutics, Inc. (DYN) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Dyne Therapeutics, Inc. (DYN) Bundle
Enhance your investment strategies with the Dyne Therapeutics, Inc. (DYN) DCF Calculator! Review the latest financial data, adjust growth projections and expenses, and instantly observe how these modifications affect the intrinsic value of Dyne Therapeutics, Inc. (DYN).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -58.3 | -148.2 | -164.8 | -233.5 | -343.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .7 | 1.1 | 3.3 | 2.5 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -59.0 | -149.3 | -168.1 | -235.9 | -343.9 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 345.3 | 376.6 | 256.0 | 123.1 | 642.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 3.4 | 4.0 | 5.3 | 22.9 | 6.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -1.2 | -3.6 | -3.1 | -.7 | -2.4 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -58.3 | -149.3 | -165.2 | -235.9 | -343.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -55.4 | -151.2 | -163.7 | -216.5 | -362.6 | -6.6 | .0 | .0 | .0 | .0 |
| WACC, % | 9.17 | 9.18 | 9.17 | 9.18 | 9.18 | 9.18 | 9.18 | 9.18 | 9.18 | 9.18 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -6 | |||||||||
| Net Debt | -411 | |||||||||
| Equity Value | 405 | |||||||||
| Diluted Shares Outstanding, MM | 94 | |||||||||
| Equity Value Per Share | 4.31 |
What You Will Get
- Real DYN Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures to fit your analysis.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Dyne Therapeutics' future performance.
- User-Friendly Design: Designed for professionals while remaining accessible to newcomers.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, revenue forecasts, and R&D expenditures.
- Instant Valuation Insights: Automatically computes intrinsic value, NPV, and other financial metrics in real-time.
- High-Precision Analytics: Leverages Dyne Therapeutics’ actual financial data for accurate valuation results.
- Streamlined Scenario Testing: Easily explore various assumptions and evaluate different outcomes.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Dyne Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Dyne Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Dyne Therapeutics, Inc. (DYN)?
- Accurate Data: Utilize real Dyne Therapeutics financial data for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth projections, WACC, and tax rates to fit your specific needs.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear step-by-step guidance make it accessible for everyone.
Who Should Use Dyne Therapeutics, Inc. (DYN)?
- Individual Investors: Gain insights to make informed decisions about investing in Dyne Therapeutics.
- Financial Analysts: Enhance your analysis with comprehensive financial models tailored for Dyne Therapeutics.
- Consultants: Provide clients with expert valuation insights related to Dyne Therapeutics efficiently and effectively.
- Business Owners: Learn from Dyne Therapeutics' valuation to inform your own business strategies.
- Finance Students: Explore valuation methodologies using real data from Dyne Therapeutics for practical learning.
What the Template Contains
- Pre-Filled DCF Model: Dyne Therapeutics, Inc. (DYN)’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Dyne Therapeutics, Inc. (DYN)’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.